Unstable Hemoglobins

Article written and reviewed by Dr Luca Moretti

Unstable hemoglobins are a heterogeneous group of inherited hemoglobinopathies characterized by a tendency of the hemoglobin molecule to denature and precipitate within red blood cells. These structural abnormalities, generally due to point mutations in genes encoding globin chains, cause loss of molecular stability that may result in chronic hemolytic anemia of variable severity. Although rare compared with other hemoglobinopathies, unstable hemoglobins are an important cause of unexplained anemia, especially in children and in cases without a family history of other inherited anemias.

The principal pathophysiologic mechanism is easy denaturation of hemoglobin and formation of intracytoplasmic inclusions known as Heinz bodies, which alter red-cell structure and function and make the cells susceptible to premature destruction, or hemolysis, particularly during oxidative stress or in the presence of predisposing chemical or pharmacologic agents.

Clinical presentation is extremely variable, ranging from asymptomatic or mild forms to severe disease with chronic hemolytic anemia, jaundice, splenomegaly, acute hemolytic crises and, in the most severe cases, complications of iron overload. Diagnosis requires a high index of clinical suspicion, recognition of characteristic laboratory findings and confirmation by molecular genetic analysis.

Understanding the structural basis, pathophysiology and general management principles of unstable hemoglobins is essential for guiding the diagnostic and therapeutic pathway and distinguishing these disorders from acquired hemolytic anemias or other hemoglobinopathies.

Molecular Structure of Hemoglobin and Basis of Instability

The principal fetal and adult hemoglobins are tetrameric proteins composed of two alpha chains and two non-alpha chains, beta, gamma or delta, each associated with a heme group responsible for reversible oxygen transport. The stability of each tetramer depends on the integrity of interactions among globin chains, three-dimensional conformation and the ability to maintain the native structure even under physiologic stress.

In unstable hemoglobins, genetic variants including point mutations, deletions, elongations and other structural alterations may destabilize one globin chain, impairing hydrophobic packing of the molecular core, integrity of the heme pocket or proper interaction among subunits. These abnormalities cause:

• A tendency toward spontaneous or accelerated hemoglobin denaturation within the red blood cell
• Formation of protein precipitates, or Heinz bodies, visible with specific stains
• Variable reduction in the amount of functional hemoglobin and increased susceptibility to oxidative injury

Unstable hemoglobin rapidly becomes a target of cellular detoxification systems and proteases, but the excess protein burden often exceeds the capacity of red-cell mechanisms, leading to membrane injury, cellular rigidity and shortened red-cell survival.

These processes may result in chronic hemolytic anemia, which becomes clinically more relevant particularly in the presence of additional factors such as oxidative stress, infections or oxidant drugs. Knowledge of the molecular basis of instability is fundamental for understanding the pathophysiology of hemolytic crises and distinguishing unstable hemoglobins from other causes of hemolysis.

Etiology and Genetics

The etiology of unstable hemoglobins consists of inherited genetic mutations that mainly involve alpha- or beta-globin genes and, more rarely, gamma- or delta-globin genes. In most cases these mutations are point mutations that produce substitution of a single amino acid, with consequent alteration of the secondary or tertiary structure of the affected globin. Inheritance is generally autosomal dominant; de novo mutations have also been described.

Most unstable variants involve the beta chain of hemoglobin A, but mutations of alpha, delta and gamma chains have also been identified. Some of the best known and most extensively studied unstable hemoglobins include Hb Köln, Hb Zürich, Hb Gun Hill, Hb Hasharon, Hb Mizuho, Hb Santa Ana, Hb Seattle, Hb Bibba, Hb Philly and numerous other variants often named after the location where they were identified or the laboratory of origin.

Mutations responsible for instability may act through several mechanisms:

• Alteration of hydrophobic interactions in the molecular core, with loss of structural compactness
• Introduction of bulky or charged amino acids at positions critical for molecular stability
• Modification of heme-binding sites or interfaces between globin subunits
• Creation of new sites susceptible to oxidation or proteolytic attack

The final result is a tendency of the molecule to lose its native conformation and precipitate within the red blood cell, especially during oxidative stress or changes in pH and temperature.

Unstable hemoglobin variants are relatively rare and their prevalence is probably underestimated because mild clinical presentations may go unrecognized, whereas more severe forms are often diagnosed early because of symptom intensity. In most cases there is no characteristic geographic distribution, although some mutations have been described more frequently in particular populations or families.

Drugs, toxins and other oxidative stresses may denature normal hemoglobin and promote Heinz body formation, but they do not constitute acquired structural unstable hemoglobins; unstable globin variants are genetic conditions.

Pathogenesis and Pathophysiology

The pathogenesis of unstable hemoglobins is dominated by the tendency of the altered molecule to denature spontaneously within the red blood cell, producing protein precipitates that accumulate as Heinz bodies attached to the cell membrane. This marked spontaneous tendency, which is not a property of physiologic hemoglobin under baseline conditions, results from loss of conformational stability and abnormal interactions between exposed hydrophobic regions of the mutated chains.

Accumulation of Heinz bodies and denatured hemoglobin causes:

• Direct injury to the red-cell membrane, with fragility, loss of elasticity and exposure of neoantigens
• Greater susceptibility to intravascular and especially extravascular hemolysis in the spleen and liver
• Alteration of redox metabolism with reduced tolerance of oxidative stress
• Variable oxygen affinity, which may be increased, reduced or normal depending on the specific variant

Red blood cells containing unstable hemoglobin have a shortened lifespan: hemoglobin precipitation and membrane injury predominantly promote splenic removal and extravascular hemolysis, with a possible intravascular component during more intense crises.

The principal pathophysiologic consequences include:

• Chronic hemolytic anemia of variable degree, with a tendency to worsen during infections, stress, exposure to oxidant drugs or associated enzyme deficiencies such as G6PD deficiency
• Jaundice due to indirect hyperbilirubinemia and splenomegaly due to increased splenic phagocytic activity
• Acute hemolytic crises, sometimes severe, especially in response to drugs or oxidant agents
• Progressive iron overload in patients who require chronic transfusions
• Presence of morphologically abnormal red blood cells, including polychromasia, anisopoikilocytosis, bite cells and blister cells; Heinz bodies can be demonstrated with supravital staining on the peripheral smear

The clinical phenotype is extremely variable: some variants cause mild anemia compatible with a normal life, whereas others present as severe neonatal forms that may require continuing transfusion support.

The pathophysiology of hemoglobin instability requires particular attention to management of additional risk factors: avoid oxidant drugs, monitor infections carefully and assess for associated conditions that may worsen the red-cell oxidative balance.

Classification and Epidemiology

Unstable hemoglobins comprise an extremely heterogeneous group of hemoglobin variants whose classification is based primarily on molecular criteria, including the type of mutation and globin chain involved, but also on phenotypic criteria, including severity of anemia, need for transfusion therapy and the associated clinical picture.

From a molecular perspective, unstable hemoglobins are divided into:

• Beta-chain variants: these account for most cases and include many classic forms such as Hb Köln, Hb Zürich and Hb Santa Ana
• Alpha-chain variants: less frequent but responsible for similar clinical presentations, often identified in the neonatal or pediatric period
• Rare gamma- or delta-chain variants: extremely uncommon and generally described in individual cases or families

Many variants are named after the geographic location or center in which they were first identified, following a longstanding tradition in hematology.

Clinically, the following forms can be distinguished:

• Mild or silent forms: characterized by no clinically evident anemia or by minimal or compensated hemolysis, often unrecognized until adulthood or identified incidentally
• Moderate forms: with chronic hemolytic anemia, mild jaundice, splenomegaly and persistent reticulocytosis
• Severe forms: neonatal or pediatric onset, severe anemia, transfusion dependence, early complications of iron overload and possible need for splenectomy

Severity depends on the specific mutation, the presence of concomitant factors and the compensatory capacity of marrow erythropoiesis.

Unstable hemoglobins are considered rare disorders. Exact prevalence is unknown and varies according to the population studied and the availability of molecular diagnostics. Their true incidence is probably underestimated because of phenotypic variability and diagnostic difficulty.

There are no geographic areas with a significantly increased prevalence, although some variants have been described more frequently in certain populations or families because of founder effects or consanguinity. Distribution is global, with reports from Europe, Asia, the Americas and Africa.

The absence of a characteristic sex-linked or geographic transmission pattern, marked clinical variability and occurrence of de novo forms mean that diagnosis always requires a high level of clinical awareness even without a positive family history.

Clinical Manifestations

The clinical picture of unstable hemoglobins is extremely variable and depends both on mutation type and on the degree of molecular instability. The phenotype ranges from subclinical or compensated forms to chronic hemolytic anemia of variable severity and severe forms often diagnosed during the neonatal period or first years of life.

The principal symptoms include:

• Chronic pallor and fatigue, proportional to the degree of anemia
• Intermittent or persistent jaundice related to hemolysis and indirect hyperbilirubinemia
• Splenomegaly, especially common in moderate and severe forms and sometimes associated with hepatomegaly
• Frequent reticulocytosis in hemolytic forms, reflecting erythropoietic compensation

In the most severe cases, particularly variants with marked instability, findings include:

• Acute hemolytic crises triggered by infections, fever, oxidant drugs or metabolic stress
• Transfusion dependence, with a risk of iron overload
• Complications of severe anemia, including growth delay, cardiomegaly, heart failure and impaired pubertal development in children
• In newborns, severe jaundice and sometimes a need for exchange transfusion

On physical and laboratory assessment, the peripheral blood smear may variably show anisopoikilocytosis, polychromasia, bite or blister cells, spherical or oval cells and, in the most severe forms, circulating erythroblasts; when present, Heinz bodies can be demonstrated with supravital stains such as brilliant cresyl blue.

The clinical presentation may be confused with other inherited hemolytic anemias, including spherocytosis, G6PD deficiency and rare hemoglobinopathies, making diagnosis late or incidental in some cases. Symptoms may be minimal or absent in mild forms, whereas severe forms are often diagnosed because of progressive neonatal anemia.

The tendency to develop hemolytic crises during infections, use of oxidant drugs or exposure to toxic substances is a characteristic feature and requires particular attention in patient management, especially in children.

Investigations and Diagnosis

The diagnosis of an unstable hemoglobin requires a rigorous sequential pathway integrating clinical suspicion, targeted laboratory tests and molecular analysis. The history must gather information about recurrent episodes of hemolytic anemia, family history of hematologic disorders, hemolytic crises following infections or medication exposure and signs of iron overload at a young age.

Suspicion arises in the presence of chronic hemolytic anemia of unidentified cause, with findings such as:

• Reduced hemoglobin associated with persistent reticulocytosis
• Marked anisopoikilocytosis, polychromasia and Heinz bodies on the peripheral smear, visible after staining with brilliant cresyl blue or crystal violet
• Increased LDH and indirect bilirubin, with reduced haptoglobin
• Splenomegaly and sometimes hepatomegaly

These findings must be assessed in the clinical context and differentiated from other causes of inherited hemolysis, including spherocytosis, G6PD deficiency and other hemoglobinopathies.

A useful diagnostic feature is recognition of Heinz bodies: their presence together with a negative direct antiglobulin test supports suspected nonimmune hemolysis with oxidative injury, but is not specific for an unstable hemoglobinopathy and requires differentiation from G6PD deficiency, oxidant exposure and other causes. Conventional hemoglobin electrophoresis may be normal or only mildly abnormal because unstable hemoglobins tend to precipitate and may not be detected as abnormal fractions. Stability tests can support the diagnosis; definitive confirmation is obtained by molecular analysis of globin genes.

To confirm the diagnosis, hemoglobin stability tests are performed:

• Heat instability test: assesses the tendency of hemoglobin to precipitate at 50-60°C
• Isopropanol test: assesses hemoglobin solubility in the presence of alcohols

These tests can support screening but have variable sensitivity, and a negative result does not exclude an unstable hemoglobin; definitive confirmation is obtained through molecular analysis of globin genes, by direct sequencing or NGS, which identifies the responsible mutation.

In severe forms, diagnosis may be established during the neonatal period, particularly in severe anemia, early jaundice and a need for transfusions. In intermediate or mild forms, diagnosis is often delayed and may occur during investigation of chronic anemia, splenomegaly or family screening.

In chronic hemolytic anemia with Heinz bodies and positive stability tests, it is always appropriate to exclude G6PD deficiency and other acquired or inherited causes of hemolysis before proceeding to genetic investigations.

Treatment and Prognosis

Management of unstable hemoglobins requires an individualized approach based on clinical severity and the presence of complications. In mild forms, treatment may be limited to clinical observation and patient education about risk factors to avoid. Moderate or severe forms require careful hematologic follow-up, supportive therapies and, in selected cases, specific procedures.

The main components of treatment include:

• Avoid oxidant drugs and exposures recognized as precipitants for the specific variant and treat infections promptly
• Prompt management of infections and other stressful conditions that increase the risk of hemolysis
• Transfusion therapy: reserved for acute episodes of severe anemia or chronic forms requiring maintenance of hemoglobin levels to support normal growth and prevent complications
• Splenectomy: indicated in selected cases of massive splenomegaly, hypersplenism or transfusion dependence that cannot otherwise be controlled. Appropriate vaccination is required before the procedure; after splenectomy, antibiotic prophylaxis is indicated according to age and risk profile
• Iron chelation therapy: for patients requiring chronic transfusions, to prevent iron overload and related organ complications
• Nutritional support and folic acid supplementation to support erythropoiesis

In very rare selected severe cases, particularly with a transfusion-dependent phenotype not controlled with supportive care, allogeneic hematopoietic stem cell transplantation may be considered as a potentially curative option in specialist centers.

Emerging therapeutic approaches such as gene therapy or gene editing remain experimental and are not currently applicable to routine clinical management of unstable hemoglobins.

Prognosis varies considerably according to the specific mutation and severity of clinical presentation. In mild forms, quality of life and life expectancy are comparable to those of the general population provided that triggers of hemolytic crises are avoided. In moderate and severe cases, long-term survival depends on management of complications, including severe anemia, iron overload and post-splenectomy infection risk, and on access to specialist care.
Early identification of the disease, patient education and multidisciplinary follow-up make it possible in most cases to prevent major complications and ensure a good quality of life.

Complications

Complications of unstable hemoglobins are the principal long-term risk, particularly in moderate and severe forms. They arise from the direct consequences of chronic hemolytic anemia, any iron overload secondary to transfusions and therapeutic procedures such as splenectomy.

The principal complications include:

• Iron overload: may develop particularly in patients receiving repeated transfusions and must be documented with appropriate monitoring. Tissue iron deposition causes hepatic injury, including hemosiderosis and cirrhosis; cardiac injury, including cardiomyopathy; endocrine injury, including diabetes and hypogonadism; as well as renal and cutaneous injury.
• Massive splenomegaly and hypersplenism: may lead to severe cytopenias, including anemia, leukopenia and thrombocytopenia, and increased risk of infections and bleeding complications. In patients treated with splenectomy there is greater susceptibility to infections with encapsulated organisms, including pneumococcus, meningococcus and Haemophilus, with a risk of fulminant sepsis.
• Acute hemolytic crises: triggered by infections, oxidative stress, drugs or environmental agents, they may cause severe acute anemia and require urgent intervention.
• Skeletal and growth complications: may occur in severe chronic forms in relation to persistent anemia, transfusion dependence and possible endocrine complications.
• Cardiac and renal complications: related both to chronic anemia and iron overload, with a risk of heart failure, arrhythmias and renal tubular injury.
• Treatment-related complications: iron chelation therapy may cause adverse effects, including cytopenias, hepatic and renal toxicity and skin reactions, whereas splenectomy is associated with increased risk of venous thrombosis and sepsis.

In some cases, particularly severe hemolytic crises may require exchange transfusion, especially in newborns, or may lead to multiorgan failure if not recognized and treated promptly.

Prevention and management of complications require multidisciplinary monitoring: regular assessment of iron stores with ferritin and T2* MRI, organ function including heart, liver, kidneys and endocrine system, vaccination, post-splenectomy antibiotic prophylaxis and counseling regarding drugs and high-risk behaviors.

Overall, the long-term outcome of patients with unstable hemoglobins depends critically on early diagnosis, adherence to follow-up and prompt management of complications, particularly iron overload and infectious risk.

References
1. Bunn HF, Forget BG. Hemoglobin: Molecular, Genetic and Clinical Aspects. WB Saunders. 1986.
2. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge University Press. 2nd ed. 2009.
3. Forget BG, Bunn HF. Classification of the disorders of hemoglobin. Cold Spring Harb Perspect Med. 2013;3(2):a011684.
4. Bain BJ. Haemoglobinopathy Diagnosis. Wiley-Blackwell. 3rd ed. 2020.
5. Williamson D. The unstable haemoglobins. Blood Rev. 1993;7(3):146–163.
6. Thom CS, Dickson CF, Gell DA, Weiss MJ. Hemoglobin variants: biochemical properties and clinical correlates. Cold Spring Harb Perspect Med. 2013;3(3):a011858.
7. Gallagher PG. Diagnosis and management of rare congenital nonimmune hemolytic disease. Hematology Am Soc Hematol Educ Program. 2015;2015:392–399.
8. Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology. Wiley-Blackwell. 7th ed. 2016.
9. Greer JP, et al. Wintrobe’s Clinical Hematology. Wolters Kluwer. 14th ed. 2019.
10. Bain BJ, Daniel Y, Henthorn J, de la Salle B, Hogan A, Roy NBA, et al.; British Society for Haematology. Significant haemoglobinopathies: A guideline for screening and diagnosis. Br J Haematol. 2023;201(6):1047-1065.